Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure

Abstract

Objective

Anemia is a frequent comorbidity in chronic heart failure (CHF) adversely affecting patients’ prognosis. Erythropoietin seems to improve exercise capacity in CHF patients. This study investigates the effects of recombinant human erythropoietin analog darbepoetin-α on quality of life and emotional stress, evaluated by relevant questionnaires in patients with CHF and anemia.

Methods

Forty-one CHF patients [New York Heart Association class: II-III; left ventricular (LV) ejection fraction (EF) ≤40%; hemoglobin < 12.5 g/dl; serum creatinine < 2.5 mg/dl] were randomized (1:1) to receive either 3-month darbepoietin-α at 1.5 μg/Kg every 20 days plus iron orally (n = 21) or placebo plus iron orally (n = 20). Echocardiographic LVEF, questionnaires addressing quality of life (Kansas City Cardiomyopathy Questionnaire, functional and overall, Duke's Activity Status Index) and emotional stress [Zung self-rating depression scale (SDS), Beck Depression Inventory], as well as plasma b-type natriuretic peptide and 6-min walking distance (6MWT as a marker of exercise capacity) were assessed at baseline and posttreatment.

Results

A significant improvement in LVEF (32 ± 6 from 26 ± 6%, P < 0.001), 6MWT (274 ± 97 from 201 ± 113m, P < 0.01), hemoglobin (12.8 ± 1.4 from 10.9 ± 1.0 g/dl, P < 0.001) and plasma b-type natriuretic peptide (517 ± 579 from 829 ± 858 pg/ml, P = 0.002) was observed posttreatment only in darbepoetin-treated group. Kansas City Cardiomyopathy Questionnaire functional (78 ± 14 from 57 ± 24%, P < 0.01) and overall (68 ± 20 from 47 ± 22, P < 0.001), Duke's Activity Status Index (19 ± 11 from 14 ± 9, P < 0.05), Zung SDS (38 ± 10 from 47 ± 11, P < 0.05) and Beck Depression Inventory (11 ± 9 from 16 ± 10, P < 0.05) scores also improved in darbepoetin-treated patients, whereas they remain unchanged in the placebo group except for the Zung SDS which worsened (P≤0.05). A significant correlation between drug-induced percent changes in 6MWT and Zung SDS (r = –0.627, P < 0.05) was also observed.

Conclusions

Darbepoetin-α improves quality of life and emotional stress in CHF patients with anemia, with a parallel increase in exercise capacity.

Keywords

anemia erythropoietin heart failure psychosocial factors quality of life

Get full access to this article

View all access options for this article.

References

Ezekowitz

McAlister

Armstrong

PW.

Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12.065 patients with new-onset heart failure. Circulation 2003; 107: 223–225.

Felker

Adams

Jr Gattis

O'Connor

CM.

Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol 2004; 44: 959–966.

Tang

Y-D

Katz

SD.

Anemia in chronic heart failure: prevalence, clinical correlates and treatment options. Circulation 2006; 113:2454–2461.

4 Silverberg

Wexler

Blum

Keren

Sheps

Leibovitch

et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000; 35:1737–1744.

Mancini

Katz

Lang

LaManca

Hudaihed

Androne

Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003; 107:294–299.

6 Ponikowski

Anker

Szachniewicz

Okonko

Ledwidge

Zymlinski

et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2007; 49:753–762.

7 Van Veldhuisen

Dickstein

Cohen-Solal

Lok

Wasserman

Baker

et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heat failure and anemia. Eur Heart J 2007; 28:2208–2216.

8 Ghali

Anand

Abraham

Fonarow

Greenberg

Krum

et al., Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008; 117:526–535.

9 Silverberg

Wexler

Sheps

Blum

Keren

Baruch

et al. The effect of correction of mild anemia in severe, resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001; 37:1775–1780.

10.

10 Palazzuoli

Silverberg

Iovine

Capobianco

Giannotti

Calabro

et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 2006; 152:1096e9–1096e15.

11.

Henry

Bowers

Romano

Provenzano

Epoetin alfa: clinical evolution of a pleiotropic cytokine. Arch Intern Med 2004; 164:262–276.

12.

12 Cleland

Sullivan

Ball

Horowitz

Agoram

Rosser

et al. Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia: a pharmacokinetic and pharmacodynamic investigation. J Cardiovasc Pharmacol 2005; 46:155–161.

13.

Vansteenkiste

Every 3 weeks dosing with darbepoetin alfa: a new paradigm in anaemia management.

Cancer Treat Rev 2006; 32 (Suppl 2): S11–S15.

14.

Green

Porter

Bresnahan

Spertus

JA.

Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 2000; 35:1245–1255.

15.

Arena

Humphrey

Peberdy

MA.

Using the Duke Activity Status Index in heart failure. J Cardiopulm Rehabil 2002; 22:93–95.

16.

Beck

Steer

Garbin

MG.

Psychometric properties of Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev 1988; 8:77–100.

17.

Zung

WWK

Richards

Short

MJ.

Self-rating depression scale in a outpatient clinic. Arch Gen Psychiatry 1965; 13:508–515.

18.

Horwich

Fonarow

Hamilton

MacLellan

Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002; 39:1780–1786.

19.

19 Komajda

Anker

Charlesworth

Okonko

Metra

Di Lenarda

et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J 2006; 27:1440–1446.

20.

Silverberg

Wexler

Iaina

The importance of anemia and its correction in the management of severe congestive heart failure. Eur J Heart Fail 2002; 4:681–686.

21.

Brophy

Ripley

Kockler

Lee

Proeschel

Darbepoetin alfa therapeutic interchange protocol for anemia in dialysis. Ann Pharmacother 2005; 39:1808–1811.

22.

Silverberg

Wexler

Blum

Iaina

Sheps

Keren

Schwartz

Erythropoietin in heart failure. Semin Nephrol 2005; 25:397–403.

23.

van der Meer

Voors

Lipsic

van Gilst

van Veldhuisen

Erythropoietin in cardiovascular diseases. Eur Heart J 2004; 25:285–291.

24.

24 Kourea

Parissis

Farmakis

Panou

Paraskevaidis

Venetsanou

et al. Effects of darbepoetin-alpha on plasma proinflammatory cytokines, anti-inflammatory cytokine interleukin-10 and soluble Fas/Fas ligand system in anemic patients with chronic heart failure. Atherosclerosis 2007 [Epub ahead of print].

25.

25 van der Meer

Lipsic

Henning

Boddeus

van der Velden

et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005; 46:125–133.

26.

26 Calvillo

Latini

Kajstura

Leri

Anversa

Ghezzi

et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A 2003; 100:4802–4806.

27.

Parissis

Adamopoulos

Rigas

Kostakis

Karatzas

Venetsanou

Kremastinos

DT.

Comparison of circulating proinflammatory cytokines and soluble apoptosis mediators in patients with chronic heart failure with versus without symptoms of depression. Am J Cardiol 2004; 94:1326–1328.

28.

Ferketich

Ferguson

Binkley

PF.

Depressive symptoms and inflammation among heart failure patients. Am Heart J 2005; 150:132–136.

29.

29 Li

Takemura

Okada

Miyata

Maruyama

et al. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res 2006; 71:684–694.

30.

30 Jiang

Alexander

Christopher

Kuchibhatla

Gaulden

Cuffe

et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 2001; 161:1849–1856.

31.

Joynt

Whelan

O'Connor

CM.

Why is depression bad for the failing heart? A review of the mechanistic relationship between depression and heart failure. J Card Fail 2004; 10:258–270.

32.

van Veldhuidsen

McMurray

JV.

Are erythropoietin stimulating proteins safe and efficacious in heat failure? Why we need an adequately powered randomised outcome trial. Eur J Heart Fail 2007; 9:110–112.